Wadler S, Schwartz E L
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467.
Cancer Chemother Pharmacol. 1994;35(1):21-30. doi: 10.1007/BF00686280.
Biochemical modulation of cytotoxic cancer chemotherapeutic agents is one means of enhancing the activity and selectivity of antitumor drugs. Traditionally this approach has utilized detailed information regarding a particular enzymatic reaction or biochemical pathway to develop potential modulating agents. In contrast, the reported clinical therapeutic activity of IFN in combination with cytotoxic agents has prompted a reexamination of the biochemical actions of the cytokine. Interferon elicits a number of cellular actions that might contribute to its pharmacologic activity, including both direct antitumor effects and host-mediated actions. The best understood are those related to the cytotoxicity of the fluoropyrimidine antimetabolites and include enzymatic reactions involved in fluoropyrimidine metabolic activation, catabolism, and interaction with its target enzyme. However, even in this instance, a mechanistic association of a specific pharmacologic action with therapeutic activity remains to be determined. These studies demonstrate that cytokines and other biologic agents may exert specific biochemical modulations that augment (or potentially attenuate) the activity of the cytotoxic chemotherapeutic agents.
细胞毒性癌症化疗药物的生化调节是增强抗肿瘤药物活性和选择性的一种手段。传统上,这种方法利用有关特定酶反应或生化途径的详细信息来开发潜在的调节剂。相比之下,干扰素与细胞毒性药物联合使用的临床治疗活性报道促使人们重新审视细胞因子的生化作用。干扰素引发了许多可能有助于其药理活性的细胞作用,包括直接抗肿瘤作用和宿主介导的作用。最被理解的是那些与氟嘧啶抗代谢物细胞毒性相关的作用,包括参与氟嘧啶代谢活化、分解代谢及其与靶酶相互作用的酶反应。然而,即使在这种情况下,特定药理作用与治疗活性的机制关联仍有待确定。这些研究表明,细胞因子和其他生物制剂可能发挥特定的生化调节作用,增强(或潜在减弱)细胞毒性化疗药物的活性。